Janux Therapeutics

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes.

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.42 per share a year ago.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors. “Eric and Natasha's vast experience and proven leadership in the biopharmaceutical indus.

Janux Therapeutics Announces Updates to Board of Directors

Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor microenvironment, showing promising results in clinical trials. JANX007 achieved a 50% PSA reduction in 83% of mCRPC patients at 0.2mg or higher. JANX008 showed a 100% lung tumor reduction in an NSCLC patient for 18 weeks.

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights.

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.45 billion.

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Argan

Coupang

Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.

Take the Money and Run: 3 Overbought Stocks to Sell ASAP

Viking Therapeutics

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable

Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.

Why Janux Therapeutics Stock Is Crushing It This Week

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet

Arvinas Inc

Novartis

Biotech stocks heated Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes.

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

According to a media report, among other potential moves, the biotech is considering putting itself up for sale. It has apparently received buyout offers from pharmaceutical companies.

Why Janux Therapeutics Stock Soared as the Market Sagged Today

Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)

Arcutis Biotherapeutics

Amylyx Pharmaceuticals

Seres Therapeutics

Rapt Therapeutics Inc

Revance Therapeutics

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

VKTX, JANX and these biotech stocks are surging in 2024

Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade

Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc  JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.

2 Stocks That Have More Than Tripled This Year: Are They Buys?

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.

News for Janux Therapeutics Stock (JANX)